What are kidney stones from harrison

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Searching Images

kidney stone nephrolithiasis types calcium oxalate uric acid

A multi-panel clinical photograph displaying a comparison chart of nine distinct kidney stone (nephrolithiasis) subtypes, labeled A through I. The specimens demonstrate significant morphological variation based on chemical composition. (A) Calcium oxalate monohydrate (Whewellite): brown, multi-lobed stone with concentric layers. (B) Calcium oxalate dihydrate (Weddellite): yellowish, sharp bipyramidal crystals. (C) Calcium phosphate (carbapatite): smooth, oval, light tan specimen. (D) Uric acid: small, rounded, yellowish-orange stones. (E) Ammonium urate: elongated, greyish stone with surface staining. (F) Struvite (triple phosphate): white, branched crystalline clusters characteristic of staghorn configurations. (G) 2,8-Dihydroxyadenine: reddish-brown, rounded stone with a bumpy, granular texture. (H) Cystine: yellowish stones with a characteristic hexagonal crystalline wax-like appearance. (I) Drug-induced (N-acetylsulfadiazine): irregular, reddish-pink stones with a rough, granular surface. This educational resource is designed for urological pathology and diagnostic training, emphasizing the use of visual stone analysis (morphoconstitutional study) to suggest underlying metabolic or pharmacological etiologies.

A multi-panel clinical photograph displaying a comparison chart of nine distinct kidney stone (nephrolithiasis) subtypes, labeled A through I. The specimens demonstrate significant morphological variation based on chemical composition. (A) Calcium oxalate monohydrate (Whewellite): brown, multi-lobed stone with concentric layers. (B) Calcium oxalate dihydrate (Weddellite): yellowish, sharp bipyramidal crystals. (C) Calcium phosphate (carbapatite): smooth, oval, light tan specimen. (D) Uric acid: small, rounded, yellowish-orange stones. (E) Ammonium urate: elongated, greyish stone with surface staining. (F) Struvite (triple phosphate): white, branched crystalline clusters characteristic of staghorn configurations. (G) 2,8-Dihydroxyadenine: reddish-brown, rounded stone with a bumpy, granular texture. (H) Cystine: yellowish stones with a characteristic hexagonal crystalline wax-like appearance. (I) Drug-induced (N-acetylsulfadiazine): irregular, reddish-pink stones with a rough, granular surface. This educational resource is designed for urological pathology and diagnostic training, emphasizing the use of visual stone analysis (morphoconstitutional study) to suggest underlying metabolic or pharmacological etiologies.

This composite educational image demonstrates the post-processing analysis of a dual-energy computed tomography (DECT) scan for nephrolithiasis characterization. The top panel contains three axial non-contrast CT sections of the kidney, showing regions of interest (ROI) labeled 3, 4, and 5 identifying small renal calculi. Below, a stone composition scatter plot correlates 'Low energy [HU]' on the x-axis with 'High energy [HU]' on the y-axis. The graph features two reference slope lines: a red line for Uric Acid and a blue line for Calcium Oxide (Ca Oxide). Data points for specific stones are plotted against these lines; proximity to the red slope suggests uric acid composition, while proximity to the blue slope indicates calcium-based stones. A accompanying table provides quantitative metrics for each ROI, including Mean Hounsfield Units (HU), Standard Deviation (SD), and Volume (ml) for both low and high-energy spectra. This tool is clinically used to non-invasively differentiate stone types, such as uric acid from calcium oxalate, which informs surgical planning and medical management strategies.

This composite educational image demonstrates the post-processing analysis of a dual-energy computed tomography (DECT) scan for nephrolithiasis characterization. The top panel contains three axial non-contrast CT sections of the kidney, showing regions of interest (ROI) labeled 3, 4, and 5 identifying small renal calculi. Below, a stone composition scatter plot correlates 'Low energy [HU]' on the x-axis with 'High energy [HU]' on the y-axis. The graph features two reference slope lines: a red line for Uric Acid and a blue line for Calcium Oxide (Ca Oxide). Data points for specific stones are plotted against these lines; proximity to the red slope suggests uric acid composition, while proximity to the blue slope indicates calcium-based stones. A accompanying table provides quantitative metrics for each ROI, including Mean Hounsfield Units (HU), Standard Deviation (SD), and Volume (ml) for both low and high-energy spectra. This tool is clinically used to non-invasively differentiate stone types, such as uric acid from calcium oxalate, which informs surgical planning and medical management strategies.

This composite of endoscopic clinical photographs demonstrates the Endoscopic Stone Recognition (ESR) of various nephrolithiasis types. Panel A1 shows a calcium oxalate monohydrate (COM) stone with a characteristic dark-brown, mammillary surface anchored to a renal papilla via Randall's plaque. A2 displays a COM stone transection revealing a radiating crystalline structure originating from a central nucleus. Panel B illustrates COM subtype Id stones with a pale, brownish-yellow budding surface. Panel C depicts calcium oxalate dihydrate (COD) stones, characterized by yellow, spiculated surfaces consisting of aggregated crystals with sharp angles. Panel D shows a uric acid (UA) stone with a smooth, homogeneous orange exterior and a transected view showing concentric laminar organization around a nucleus. Panel E presents a cystine stone, identifiable by its rough, bumpy light brown-yellow surface with a distinctive waxy luster. These images serve as a diagnostic guide for intraoperative identification of stone morphology to inform metabolic etiology and recurrence risk.

This composite of endoscopic clinical photographs demonstrates the Endoscopic Stone Recognition (ESR) of various nephrolithiasis types. Panel A1 shows a calcium oxalate monohydrate (COM) stone with a characteristic dark-brown, mammillary surface anchored to a renal papilla via Randall's plaque. A2 displays a COM stone transection revealing a radiating crystalline structure originating from a central nucleus. Panel B illustrates COM subtype Id stones with a pale, brownish-yellow budding surface. Panel C depicts calcium oxalate dihydrate (COD) stones, characterized by yellow, spiculated surfaces consisting of aggregated crystals with sharp angles. Panel D shows a uric acid (UA) stone with a smooth, homogeneous orange exterior and a transected view showing concentric laminar organization around a nucleus. Panel E presents a cystine stone, identifiable by its rough, bumpy light brown-yellow surface with a distinctive waxy luster. These images serve as a diagnostic guide for intraoperative identification of stone morphology to inform metabolic etiology and recurrence risk.

I now have comprehensive content from Harrison's. Let me compile the full answer.

Nephrolithiasis (Kidney Stones) - Harrison's Principles of Internal Medicine, 22nd Edition

Chapter by Gary C. Curhan

Overview

Nephrolithiasis (kidney stone disease) is a common, painful, and costly condition. A stone forms from crystallization of lithogenic factors in the upper urinary tract; it can then move into the ureter and cause renal colic - widely reported by patients as the worst pain they have ever experienced. Most stone recurrences can be prevented with careful evaluation and targeted, lifelong preventive treatment.
  • Harrison's Principles of Internal Medicine 22E, p.2464

Stone Types

TypeFrequency
Calcium oxalate~75%
Calcium phosphate~15%
Uric acid~8%
Struvite~1%
Cystine<1%
Many stones are mixed (e.g., calcium oxalate + calcium phosphate) and contain protein in the matrix. Rarely, medications cause stones (acyclovir, atazanavir, triamterene). Identifying stone type is clinically important as it directs the preventive regimen.
  • Harrison's, p.2468
Here is what the major stone types look like:
Kidney stone types - morphological comparison

Epidemiology

  • Prevalence is increasing, likely due to Westernization (dietary changes, rising BMI).
  • Up to 20% of men and 10% of women will develop at least one stone in their lifetime (NHANES 2007-2016).
  • Prevalence is ~50% lower in Black individuals vs. whites.
  • Peak annual incidence in white men: ~3.5 cases/1000 at age 40.
  • Substantial economic impact as those affected are often of working age.
  • Harrison's, p.2473

Associated Medical Conditions

Nephrolithiasis is a systemic disorder. Conditions that predispose to stone formation include:
  • GI malabsorption (Crohn's disease, gastric bypass surgery)
  • Primary hyperparathyroidism
  • Obesity and type 2 diabetes mellitus
  • Distal renal tubular acidosis
Conditions more likely in stone formers include: hypertension, gout, cardiovascular disease, cholelithiasis, reduced bone mineral density, and chronic kidney disease.
  • Harrison's, p.2478

Risk Factors

Dietary Risk Factors

  • Low fluid intake / low urine volume - the single most important modifiable risk factor
  • High sodium intake - increases urine calcium
  • High animal protein intake - increases urine uric acid and calcium, decreases citrate
  • High oxalate intake - increases urine oxalate
  • Low calcium intake - paradoxically increases risk (dietary calcium binds intestinal oxalate)
  • High fructose intake - increases urine oxalate, calcium, and uric acid

Non-dietary Risk Factors

  • Highest incidence in middle-aged white men
  • Obesity, high BMI
  • Hot climate / geographic "stone belt" regions
  • Anatomic abnormalities (e.g., medullary sponge kidney, horseshoe kidney)
  • Genetic factors - monogenic disorders cause nephrolithiasis; GWAS studies reveal polygenic contributors

Urinary Risk Factors (the proximate determinants)

  • Hypercalciuria - most common urinary abnormality
  • Hyperoxaluria
  • Hypocitraturia - citrate is the main natural inhibitor of crystallization
  • Hyperuricosuria
  • Low urine volume
  • High or low urine pH (depending on stone type)
  • Harrison's, p.2494-2534

Clinical Presentation

  • Renal colic: Sudden onset severe flank pain radiating to the groin; classically colicky but often constant; nausea and vomiting common
  • Hematuria (gross or microscopic) in ~90% of cases
  • Urinary urgency/frequency when stone is near the ureterovesical junction
  • Stones <5 mm usually pass spontaneously; >10 mm unlikely to pass without intervention

Diagnosis

  • Non-contrast CT (CT-KUB): Gold standard - detects virtually all stone types, determines size and location
  • Plain X-ray (KUB): Calcium-containing stones are radiopaque; uric acid stones are radiolucent
  • Renal ultrasound: Useful to detect hydronephrosis; avoids radiation (preferred in pregnancy)
  • Urinalysis: Hematuria; crystal type may suggest stone composition; pH helps (low pH - uric acid; high pH - struvite)
  • 24-hour urine collection: Essential for metabolic evaluation in recurrent stone formers - measures calcium, oxalate, uric acid, citrate, sodium, creatinine, pH, volume

Prevention by Stone Type

Calcium Oxalate

  • Increase fluid intake (goal urine volume >2 L/day)
  • Reduce sodium and animal protein
  • Maintain adequate dietary calcium (~1200 mg/day with meals)
  • Thiazide diuretics (e.g., hydrochlorothiazide, indapamide, chlorthalidone) - reduce urine calcium
  • Potassium citrate - increases urine citrate, reduces crystallization
  • DASH diet or Mediterranean diet - strong observational data for reduced stone risk

Calcium Phosphate

  • Same as above for calcium oxalate
  • Monitor urine pH (supplemental alkali can worsen by raising pH - since these patients already have high pH)
  • Reduce dietary phosphate
  • Harrison's, p.2665-2667

Uric Acid

  • Urine pH is the key factor - uric acid stones form at persistently low pH
  • Alkali supplementation (potassium citrate/bicarbonate) - goal urine pH 6.5 throughout day and night
  • Reduce purine-containing foods (animal flesh)
  • Increase fruits and vegetables
  • If above measures fail: xanthine oxidase inhibitor (allopurinol or febuxostat) reduces urine uric acid by 40-50%
  • Note: serum uric acid does NOT reliably predict urine uric acid excretion
  • Harrison's, p.2669-2671

Cystine

  • High fluid intake is essential (highest priority)
  • Tiopronin (preferred) or D-penicillamine - bind cystine covalently to increase solubility
  • Potassium citrate/bicarbonate to alkalinize urine (goal pH 7.5)
  • Avoid sodium salts (sodium increases cystine excretion)
  • Harrison's, p.2673

Struvite (Infection Stones)

  • Form only when the upper urinary tract is infected with urease-producing bacteria (e.g., Proteus mirabilis, Klebsiella)
  • Urease splits urea into ammonium, raising urine pH to 7.2-8.0 - an alkaline environment that precipitates magnesium ammonium phosphate
  • Also called "infection stones" or "triple-phosphate stones"
  • Can form staghorn calculi that fill the renal pelvis and calyces
  • Require complete surgical removal + eradication of the infection; stone fragments harbor bacteria and lead to recurrence
  • Harrison's, p.2675

Summary Table

Stone TypeKey Risk FactorsPrevention
Calcium oxalateLow urine volume, hypercalciuria, hyperoxaluria, hypocitraturiaFluids, thiazides, K-citrate, low sodium/protein
Calcium phosphateHigh urine pH, hypercalciuria, distal RTA, hyperparathyroidismThiazides, monitor pH carefully with alkali
Uric acidLow urine pH, high purine intake, goutAlkali (K-citrate), low purine diet, allopurinol
StruviteUrease-producing UTIComplete stone removal + antibiotics
CystineCystinuria (genetic)Tiopronin, K-citrate, high fluid intake

Source: Harrison's Principles of Internal Medicine, 22nd Edition (2025), Chapter: Nephrolithiasis by Gary C. Curhan
This is a shared conversation. Sign in to Orris to start your own chat.